Fate Therapeutics Inc (FATE) 6.46 $FATE
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014
GlobeNewswire - Tue May 06, 6:05AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 13, 2014, at 5:00 p.m. EDT to report its first quarter 2014 financial results and to provide a corporate update.
Fate Therapeutics to Present at Deutsche Bank 39th Annual Health Care Conference
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company at the Deutsche Bank 39 Annual Healthcare Conference in Boston, MA. The presentation will take place at The InterContinental Hotel on Wednesday, May 7, 2014 at 10:00 a.m. EDT.
Global Cachexia Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggqhv/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Plexxikon Inc. - BioLineRx, Ltd. - Novartis AG - Aphios Corporation - Calzada Limited - Palatin Technologies, Inc. - Cytokinetics, Incorporated - Fate Therapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Fountain Biopharma Inc. - Rhythm Pharmaceuticals - MI.TO. Technology S.r.L. For more information visit http://www.researchandmarkets.com/research/pggqhv/cachexia
Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients
GlobeNewswire - Wed Apr 23, 6:01AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) amendment to evaluate PROHEMA in pediatric patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of hematologic malignancies. The FDA's clearance of the IND amendment allows the Company to expand its clinical investigation of PROHEMA, which to date has only been administered to adults, in pediatric patients as young as one year of age. The Company plans to initiate enrollment of the "PROMPT" (PROHEMA for the treatment of hematologic Malignancies in PediaTric patients undergoing single umbilical cord blood transplantation) study, which is designed to enroll up to 18 patients, between the ages of 1 and 18, at three leading U.S. pediatric transplant centers in mid-2014.
Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics
GlobeNewswire - Thu Apr 10, 6:01AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Patent and Trademark Office (PTO) has issued Patent No. 8,691,573 entitled "Stem Cell Cultures." The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase (ROCK) that are crucial to the therapeutic application of human induced pluripotent stem cells (hiPSCs). Modulators belonging to the patented class have been shown to be necessary for the high-throughput derivation of transgene-free hiPSCs, and for the maintenance, survival and genomic stability of hiPSCs in culture. Fate Therapeutics holds an exclusive license from The Scripps Research Institute (TSRI) to the patent in all commercial fields.
Fate Therapeutics (FATE) Falls: Stock Goes Down 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:37AM CDT
Fate Therapeutics has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Fate Reports In-Line Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:28PM CDT
Share price of Fate Therapeutics (FATE) gained 10.3% after the company released fourth quarter earnings but lost 4.0% in the next trading session. Overall, shares gained 6.15% following the fourth quarter results.
Fate Therapeutics adds Dr Robert S. Epstein to board
M2 - Tue Mar 18, 5:41AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) reported on Monday the election of Dr Robert S. Epstein, MD to its board of directors.
Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 17, 3:01PM CDT
Phase 2 PUMA Study of PROHEMA(R) Initiated - Interim Data Expected in 2H14
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
Fate Therapeutics' Prohema in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:50AM CDT
Fate Therapeutics' Prohema enters phase II study
Fate Therapeutics enrolls first patient in Phase 2 clinical trial of PROHEMA under PUMA study for treating hematologic malignancies
M2 - Thu Mar 13, 4:25AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) disclosed on Wednesday the admission of the first patient in its "PUMA" study under its Phase 2 clinical trial of PROHEMA in patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of hematologic malignancies.
Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies
GlobeNewswire - Wed Mar 12, 6:01AM CDT
First Patient Enrolled in PUMA Study
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014
GlobeNewswire - Tue Mar 11, 6:02AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Monday, March 17, 2014, at 5:00 p.m. EDT to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics
GlobeNewswire - Thu Mar 06, 6:09AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the publication of an article in the journal Stem Cell Reports by Fate scientists demonstrating high-throughput derivation of human induced pluripotent stem cells (hiPSCs) that exhibit characteristics necessary for therapeutic application. The publication describes the use of the Company's hiPSC platform, consisting of stage-specific cell culture systems, to enable rapid, parallel derivation of hiPSC clones and their subsequent expansion as transgene-free, single cells in culture. The Company's proprietary combinations of small molecule modulators, which include ROCK, GSK3 and MEK pathway inhibitors, used in the culture systems were found to be critical in promoting characteristics of the ground state of pluripotency including pluripotent culture stability, homogeneity and survival.
Fate Therapeutics Observes Rare Disease Day 2014
GlobeNewswire - Fri Feb 28, 6:01AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, is joining the Muscular Dystrophy Association (MDA) and other advocacy organizations around the world today to observe Rare Disease Day.
Fate Therapeutics to Present at Upcoming March Conferences
GlobeNewswire - Thu Feb 27, 6:45AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company's programs and outlook at the following March conferences:
Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R)
GlobeNewswire - Wed Feb 26, 6:03AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the release of new data on the observed effects of ex vivo pharmacologic modulation on CD8+ T cells and immune reconstitution from its previously-completed Phase 1b clinical trial of PROHEMA (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) in adult patients undergoing hematopoietic stem cell (HSC) transplantation for hematologic malignancy (the ProHema-01 trial). Researchers affiliated with Harvard Medical School performed an analysis of the CD8+ T cell compartment using patient samples from the ProHema-01 trial. At Day 100, subjects who received PROHEMA and an unmanipulated cord blood unit (n=12) showed a two-fold increase in the percentage of naïve and early memory T cell fraction within the CD8+ T cell compartment as compared to subjects who received two unmanipulated cord blood units (n=9). These naïve and early memory CD8+ T cell populations are believed to play a key role in promoting immune reconstitution and viral immunity following cord blood transplantation. These findings were recently published in Blood Cancer Journal (Li, L. et. al. Blood Cancer Journal 2014).
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Marketwire - Thu Jan 30, 6:38AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, is pleased to announce that its Board of Directors has elected Dr. Calvin R. Stiller as Chairman of the Board. Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2014 Financial Results on May 13, 2014
GlobeNewswire - Tue May 06, 6:05AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 13, 2014, at 5:00 p.m. EDT to report its first quarter 2014 financial results and to provide a corporate update.
Fate Therapeutics to Present at Deutsche Bank 39th Annual Health Care Conference
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company at the Deutsche Bank 39 Annual Healthcare Conference in Boston, MA. The presentation will take place at The InterContinental Hotel on Wednesday, May 7, 2014 at 10:00 a.m. EDT.
Global Cachexia Therapeutics Pipeline Review 2014
M2 - Tue Apr 29, 9:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pggqhv/cachexia) has announced the addition of the "Cachexia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cachexia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Cachexia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cachexia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cachexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cachexia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - GlaxoSmithKline plc - Plexxikon Inc. - BioLineRx, Ltd. - Novartis AG - Aphios Corporation - Calzada Limited - Palatin Technologies, Inc. - Cytokinetics, Incorporated - Fate Therapeutics, Inc. - AVEO Pharmaceuticals, Inc. - Fountain Biopharma Inc. - Rhythm Pharmaceuticals - MI.TO. Technology S.r.L. For more information visit http://www.researchandmarkets.com/research/pggqhv/cachexia
Fate Therapeutics Announces FDA Clearance of IND Amendment for Clinical Development of PROHEMA(R) in Pediatric Patients
GlobeNewswire - Wed Apr 23, 6:01AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug Application (IND) amendment to evaluate PROHEMA in pediatric patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of hematologic malignancies. The FDA's clearance of the IND amendment allows the Company to expand its clinical investigation of PROHEMA, which to date has only been administered to adults, in pediatric patients as young as one year of age. The Company plans to initiate enrollment of the "PROMPT" (PROHEMA for the treatment of hematologic Malignancies in PediaTric patients undergoing single umbilical cord blood transplantation) study, which is designed to enroll up to 18 patients, between the ages of 1 and 18, at three leading U.S. pediatric transplant centers in mid-2014.
Fate Therapeutics Secures U.S. Patent for Class of Small Molecule Modulators Key to the Development of iPSC-Based Therapeutics
GlobeNewswire - Thu Apr 10, 6:01AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Patent and Trademark Office (PTO) has issued Patent No. 8,691,573 entitled "Stem Cell Cultures." The newly issued patent claims a class of small molecule inhibitors of Rho-associated kinase (ROCK) that are crucial to the therapeutic application of human induced pluripotent stem cells (hiPSCs). Modulators belonging to the patented class have been shown to be necessary for the high-throughput derivation of transgene-free hiPSCs, and for the maintenance, survival and genomic stability of hiPSCs in culture. Fate Therapeutics holds an exclusive license from The Scripps Research Institute (TSRI) to the patent in all commercial fields.
Fate Therapeutics (FATE) Falls: Stock Goes Down 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:37AM CDT
Fate Therapeutics has seen negative earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
Fate Reports In-Line Loss in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 1:28PM CDT
Share price of Fate Therapeutics (FATE) gained 10.3% after the company released fourth quarter earnings but lost 4.0% in the next trading session. Overall, shares gained 6.15% following the fourth quarter results.
Fate Therapeutics adds Dr Robert S. Epstein to board
M2 - Tue Mar 18, 5:41AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) reported on Monday the election of Dr Robert S. Epstein, MD to its board of directors.
Fate Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Mon Mar 17, 3:01PM CDT
Phase 2 PUMA Study of PROHEMA(R) Initiated - Interim Data Expected in 2H14
Fate Therapeutics Appoints Dr. Robert S. Epstein to Its Board of Directors
GlobeNewswire - Mon Mar 17, 6:40AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Dr. Robert S. Epstein, M.D., has joined its Board of Directors.
Fate Therapeutics' Prohema in Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 10:50AM CDT
Fate Therapeutics' Prohema enters phase II study
Fate Therapeutics enrolls first patient in Phase 2 clinical trial of PROHEMA under PUMA study for treating hematologic malignancies
M2 - Thu Mar 13, 4:25AM CDT
Biopharmaceutical company Fate Therapeutics (NasdaqGM:FATE) disclosed on Wednesday the admission of the first patient in its "PUMA" study under its Phase 2 clinical trial of PROHEMA in patients undergoing hematopoietic stem cell (HSC) transplantation for the treatment of hematologic malignancies.
Fate Therapeutics Commences Phase 2 Clinical Trial of PROHEMA(R) for the Treatment of Hematologic Malignancies
GlobeNewswire - Wed Mar 12, 6:01AM CDT
First Patient Enrolled in PUMA Study
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2013 Financial Results on March 17, 2014
GlobeNewswire - Tue Mar 11, 6:02AM CDT
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, today announced that the Company will host a conference call and live audio webcast on Monday, March 17, 2014, at 5:00 p.m. EDT to report its fourth quarter and full year 2013 financial results and provide a corporate update.
Fate Therapeutics Announces Publication of Its Proprietary Stem Cell Modulation Platform for Developing iPSC-Based Regenerative Therapeutics
GlobeNewswire - Thu Mar 06, 6:09AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the publication of an article in the journal Stem Cell Reports by Fate scientists demonstrating high-throughput derivation of human induced pluripotent stem cells (hiPSCs) that exhibit characteristics necessary for therapeutic application. The publication describes the use of the Company's hiPSC platform, consisting of stage-specific cell culture systems, to enable rapid, parallel derivation of hiPSC clones and their subsequent expansion as transgene-free, single cells in culture. The Company's proprietary combinations of small molecule modulators, which include ROCK, GSK3 and MEK pathway inhibitors, used in the culture systems were found to be critical in promoting characteristics of the ground state of pluripotency including pluripotent culture stability, homogeneity and survival.
Fate Therapeutics Observes Rare Disease Day 2014
GlobeNewswire - Fri Feb 28, 6:01AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, is joining the Muscular Dystrophy Association (MDA) and other advocacy organizations around the world today to observe Rare Disease Day.
Fate Therapeutics to Present at Upcoming March Conferences
GlobeNewswire - Thu Feb 27, 6:45AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that Christian Weyer, M.D., M.A.S., President and Chief Executive Officer, will present an overview of the company's programs and outlook at the following March conferences:
Fate Therapeutics Announces Observed Effects of Pharmacologic Modulation on T Cell Compartment From Its Phase 1b Study of PROHEMA(R)
GlobeNewswire - Wed Feb 26, 6:03AM CST
Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the release of new data on the observed effects of ex vivo pharmacologic modulation on CD8+ T cells and immune reconstitution from its previously-completed Phase 1b clinical trial of PROHEMA (16, 16-dimethyl prostaglandin E2, or dmPGE2, modulated cord blood) in adult patients undergoing hematopoietic stem cell (HSC) transplantation for hematologic malignancy (the ProHema-01 trial). Researchers affiliated with Harvard Medical School performed an analysis of the CD8+ T cell compartment using patient samples from the ProHema-01 trial. At Day 100, subjects who received PROHEMA and an unmanipulated cord blood unit (n=12) showed a two-fold increase in the percentage of naïve and early memory T cell fraction within the CD8+ T cell compartment as compared to subjects who received two unmanipulated cord blood units (n=9). These naïve and early memory CD8+ T cell populations are believed to play a key role in promoting immune reconstitution and viral immunity following cord blood transplantation. These findings were recently published in Blood Cancer Journal (Li, L. et. al. Blood Cancer Journal 2014).
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Marketwire - Thu Jan 30, 6:38AM CST
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS)(OTCQX: SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, is pleased to announce that its Board of Directors has elected Dr. Calvin R. Stiller as Chairman of the Board. Dr. Stiller has been a member of the Board since July 2011 and served as Lead Director and Chair of the Governance and Nominating Committee.
